Surgical approach to multifocal hepatocellular carcinoma with portal vein thrombosis and arterioportal shunt leading to portal hypertension and bleeding: a case report
© Ratti et al; licensee BioMed Central Ltd. 2012
Received: 31 October 2011
Accepted: 13 February 2012
Published: 13 February 2012
It is reported the case of a 69 years man who presented to the Emergency Room because of pain and abdominal distension from ascites. After admission and paracentesis placement, he developed a digestive hemorrhage due to oesophageal varices from portal ipertension secondary to the formation of a portal shunt concomitant with a multifocal HepatoCellular Carcinoma (HCC) with portal vein thrombosis (PVT). The patient underwent endoscopic varices ligation, twice transarterial embolization (TAE) of arterial branches feeding the shunt and subsequent left hepatectomy. During the postoperative course he developed mild and transient signs of liver failure and was discharged in postoperative day 16. He is alive and disease free 8 months after surgery.
KeywordsHCC portal vein thrombosis arterioportal shunt liver surgery
The aggressiveness and invasiveness of Hepatocellular Carcinoma (HCC) towards the main portal vein and portal vein branches frequently causes the formation of abnormal communications between vessels originating from the hepatic artery and portal vein, creating an arterioportal shunt (APS) . Hemodynamic changes resulting from the formation of this vascular abnormality tend to cause or worsen portal hypertension and therefore to increase the incidence of major complications . Transient complications of portal hypertension lead to overestimation of patient's class of risk, especially regarding postoperative liver failure: their recognition and treatment allows avoidance of inadvertent exclusion from surgery , improving long term outcome .
It is reported the case of a patient with multifocal HCC complicated by the presence of APS and portal vein thrombosis (PVT) diagnosed after an episode of digestive hemorrhage from oesophageal varices.
Patient characteristics and treatment
HCC is associated with the presence of intralesional APS regarding the common portal vein in approximately 60% , or the main portal vein branches in 30% of patients according to data reported by Okuda et al .
The presence of a high flow APS with hemodynamically significant consequences, results in the creation or worsening of portal hypertension, with potentially life threatening complications such as oesophageal varices rupture, refractory ascites, and liver encephalopaty [1–3].
The diagnosis of APS is reached through the execution of a contrast enhanced abdomen CT, revealing the absence of atypical HCC radiologic features, a clear enhancement of the portal vein axis contemporary to the hepatic artery during the arterial phase of the examination and a lack of enhancement during the arterial phase, since the blood flow to the lesion is reduced because of the APS [8, 9]. The diagnosis of multifocal HCC with APS makes two issues arising: first, the treatment of APS and, secondly, the treatment of HCC out of Barcelona criteria .
Treatment options range from medical therapy alone (Sorafenib), interventional radiology procedures (TAE to treat the APS and/or transarterial chemoembolization for the treatment of hepatic multifocal lesions) with or without medical therapy, to radiological treatment of the shunt (APS-TAE) and subsequent surgical liver resection [11–14].
In this case report, in decision-making process two sets of issues were taken into account: in the one hand, the issue of APS in patients with HCC and, in the other the treatment of hepatocellular malignancy out of Barcelona criteria.
Regarding the first point, the emergency treatment of acute bleeding from esophageal varices may be made by endoscopic ligation or sclerotherapy, and finally by TIPS or surgical shunt if the control of portal hypertension is not effective .
It is remarkable that in patients with APS the control of portal hypertension is consequent to the treatment of the shunt itself. Even if the rates of recanalization are high, as reported in the literature , in this case it was decided to proceed with embolization of arterial blood vessels feeding the shunt, with the dual aim of reducing the risk of portal hypertension related complications (also aggravated by portal vein thrombosis) and of gaining better hemostatic control intraoperatively.
The need for a double session of embolization was established by radiological finding of shunt persistence due to arterial vessels originating from the left gastric artery.
Control of portal hypertension resulted in ascites resolution and re-classification of the patient in class A5 according to Child Pugh: if not, the patient would have taken two points for ascites resulting in B7. This means that transient complications of portal hypertension tend to overestimate patient's class of risk, especially regarding postoperative liver failure. After shunt treatment indeed, the patient was reported to the appropriate class of Child and during the postoperative course, the patient developed only mild and transient signs of liver failure. Ishii et al. noted that in the presence of APS the green indocyanin retention test proved to be unreliable , since it overstates functional parenchymal impairment .
Timing for surgery has to be decided in a case by case analysis, considering the balance between complete acute complication resolution and the risk of ischemic or septic complications and APS recanalization.
A proper evaluation of the hepatic functional reserve, prevents inappropriate exclusion of patients from the only potentially curative treatment, because of risk overestimation.
In the present case report, the patient presented with multifocal disease, portal hypertension and malignant PVT: the long term prognosis of these patients is quite poor, so that Barcelona criteria do not indicate surgery as the treatment of choice, since the 5-year survival rate is less than 50% [10, 18]. Despite of this, the most experienced surgical centers continue to perform liver resection out of Barcelona indications , suggesting that good long-term results are achievable, better than those reported after non-curative treatments .
In particular, patients with PVT have a median survival of 2.7 months without treatment . On the contrary, following surgery, several authors report 3 years survival rates ranging between 0 and 43% depending on the series [21–24]. Furthermore, the presence of portal hypertension is not a contraindication itself to invasive approach or a predictor of outcome, as suggested by Capussotti  and other authors [26, 27].
In conclusion, the diagnostic and therapeutic strategy proposed in this case is aimed to both the resolution and prevention of acute complications of portal hypertension and to offer a chance of long term survival thanks to oncologic treatment. Transient complications of portal hypertension have to be corrected before deciding therapeutic strategy, as they tend to overestimate patient's class of risk and may induce inappropriate exclusion of patients from surgery that is actually able to improve long term survival.
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor in Chief of this journal.
List of abbreviations
Portal vein thrombosis
Trans arterial embolization
Post operative day.
- Lazaridis KN, Kamath PS: Images in hepatology. Arterioportal fistula causing recurrent variceal bleeding. J Hepatol. 1998, 29: 142-10.1016/S0168-8278(98)80189-X.View ArticlePubMed
- Velázquez RF, Rodríguez M, Navascués CA, Linares A, Pérez R, Sotorríos NG, Martínez I, Rodrigo L: Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology. 2003, 37: 520-527. 10.1053/jhep.2003.50093.View ArticlePubMed
- Morse SS, Sniderman KW, Galloway S, Rapoport S, Ross GR, Glickman MG: Hepatoma, arterioportal shunting, and hyperkinetic portal hypertension: therapeutic embolization. Radiology. 1985, 155: 77-82.View ArticlePubMed
- Rahbari NN, Mehrabi A, Mollberg NM, Muller SA, Koch M, Buchler MW, Weitz J: Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg. 2011, 253 (3): 453-69. 10.1097/SLA.0b013e31820d944f.View ArticlePubMed
- Clavien PA, Barkun J, de Oliveira M, Vauthey JN, Dindo D, Schulik RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vontlanthen R, Padbudy R, Cameron JL, Makuuchi M: The Clavien-Dindo classification of surgical complications. Five-years experience. Ann Surg. 2009, 250: 187-196. 10.1097/SLA.0b013e3181b13ca2.View ArticlePubMed
- Ngan H, Peh WC: Arteriovenous shunting in hepatocellular carcinoma: its prevalence and clinical significance. Clin Radiol. 1997, 52: 36-40. 10.1016/S0009-9260(97)80303-0.View ArticlePubMed
- Okuda K, Musha H, Yamasaki T, Jinnouchi S, Nagasaki Y, Kubo Y, Shimokawa Y, Nakayama T, Kojiro M, Sakamoto K, Nakashima T: Angiographic demonstration of intrahepatic arterio-portal anastomoses in hepatocellular carcinoma. Radiology. 1977, 122: 53-58.View ArticlePubMed
- Luo MY, Shan H, Jiang ZB, Liang WW, Zhang JS, Li LF: Capability of multidetector CT to diagnose hepatocellular carcinoma-associated arterioportal shunt. World J Gastroenterol. 2005, 11: 2666-2669.PubMed CentralView ArticlePubMed
- Choi BI, Lee KH, Han JK, Lee JM: Hepatic arterioportal shunts: dynamic CT and MR features. Korean J Radiol. 2002, 3 (1): 1-15. 10.3348/kjr.2002.3.1.1.PubMed CentralView ArticlePubMed
- Bruix J, Sherman M, Llovet JM, Beaugard M, Lencioni R, Burroughs AK, Christenses E, Pagliaro L, Colombo M, Rodes J, for the EASL panel of experts on HCC: Clinical management of hepatocellular carcinoma. Conclusion of the Barcelona-2000 EASL conference. Journal of Hepatology. 2001, 35: 421-430. 10.1016/S0168-8278(01)00130-1.View ArticlePubMed
- Llovet JM, Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008, 48 (Supp): 20-37.View Article
- Bruix J, Llovet JM: Major achievements in hepatocellular carcinoma. Lancet. 2009, 373: 614-616. 10.1016/S0140-6736(09)60381-0.View ArticlePubMed
- Ishii H, Sonoyama T, Nakashima S, Nagata H, Shiozaki A, Kuriu Y, Ikoma H, Nakanishi M, Ichikawa D, Fujiwara H, Okamoto K, Ochiai T, Kokuba Y, Sakakura C, Otsuji E: Surgical treatment of hepatocellular carcinoma with severe intratumoral arterioportal shunt. World J Gastroenterol. 2010, 16 (25): 3211-3214. 10.3748/wjg.v16.i25.3211.PubMed CentralView ArticlePubMed
- Mamada Y, Yoshida H, Taniai N, Bandou K, Mizuguchi Y, Kakinuma D, Ishikawa Y, Akimaru K, Tajiri T, Naito Z: Major arterioportal shunt caused by hepatocellular carcinoma. J Nihon Med Sch. 2007, 74 (4): 314-318. 10.1272/jnms.74.314.View Article
- Carey W: Portal hypertension: diagnosis and management with particular reference to variceal hemorrhagex. J Dig Dis. 2011, 12 (1): 25-32. 10.1111/j.1751-2980.2010.00473.x.View ArticlePubMed
- Huang MS, Lin Q, Jiang ZB, Zhu KS, Guan SH, Li ZR, Shan H: Comparison of long-term effects between intra-arterially delivered ethanol and Gelfoam for the treatment of severe arterioportal shunt in patients with hepatocellular carcinoma. World J Gastroenterol. 2004, 10: 825-829.PubMed
- Imamura H, Sano K, Sugawara Y, Kokudo N, Makuuchi M: Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg. 2005, 12: 16-22. 10.1007/s00534-004-0965-9.View ArticlePubMed
- Buix J, Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002, 35 (3): 519-24. 10.1053/jhep.2002.32089.View Article
- Capussotti L, Ferrero A, Viganò L, Polastri R, Tabone M: Liver resection for HCC with cirrhosis: surgical perspectives out of EASL/AASLD guidelines. Eur J Surg Oncol. 2009, 35 (1): 11-5. 10.1016/j.ejso.2007.06.005.View ArticlePubMed
- Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Brù C, Rodes J, Bruix J: Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999, 29 (1): 62-7. 10.1002/hep.510290145.View ArticlePubMed
- Yoshidome H, Takeuchi D, Kimura F, Shimizu H, Ohtsuka M, Kato A, Furukawa K, Yoshitomi H, Miyazaki M: Treatment strategy for hepatocellular carcinoma with major portal vein or inferior vena cava invasion: a single institution experience. J Am Coll Surg. 2011, 212 (5): 796-803. 10.1016/j.jamcollsurg.2011.01.002.View ArticlePubMed
- Minagawa M, Makuuchi M, Takayama T, Ohtomo K: Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg. 2001, 233 (3): 379-384. 10.1097/00000658-200103000-00012.PubMed CentralView ArticlePubMed
- Fong Y, Sun RL, Jarnagin W, Blumgart LH: An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999, 229 (6): 790-799. 10.1097/00000658-199906000-00005.PubMed CentralView ArticlePubMed
- Fuster J, Garcia-Valdecasas JC, Grande L, Tabet J, Bruix J, Anglada T, Taurà P, Lacy AM, Gonzalez X, Vilana R, Bru C, Sole M, Visa J: Hepatocellular carcinoma and cirrhosis. Results of surgical treatment in a European series. Ann Surg. 1996, 223 (3): 297-302. 10.1097/00000658-199603000-00011.PubMed CentralView ArticlePubMed
- Capussotti L, Ferrero A, Viganò L, Muratore A, Polastri R, Bouzari H: Portal hypertension: contraindication to liver surgery?. World J Surg. 2006, 30 (6): 992-999. 10.1007/s00268-005-0524-9.View ArticlePubMed
- Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, Ramacciato G, Grazi GL, Pinna AD: Is portal hypertension a contraindication to hepatic resection?. Ann Surg. 2009, 250 (6): 922-928. 10.1097/SLA.0b013e3181b977a5.View ArticlePubMed
- Imamura H, Seyama Y, Kokudo N, Maema A, Sugawara Y, Sano K, Takayama T, Makuuchi M: One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg. 2003, 138 (11): 1198-1206. 10.1001/archsurg.138.11.1198.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.